Total Price: $0.00
Contact Information
Recombinant Human LYPD3 Protein (His Tag)(Active)
SKU: PKSH033352-50
Recombinant Human LYPD3 Protein (His Tag)(Active)
| SKU # | PKSH033352 |
| Expression Host | HEK293 Cells |
Description
| Synonyms | C4.4A, GPI-Anchored Metastasis-Associated Protein C4.4A Homolog, LYPD3, Ly6/PLAUR Domain-Containing Protein 3, MIG-C4, Matrigel-Induced Gene C4 Protein |
| Species | Human |
| Expression Host | HEK293 Cells |
| Sequence | Leu31-His286 |
| Accession | O95274 |
| Calculated Molecular Weight | 27.9 kDa |
| Observed Molecular Weight | 55-75 kDa |
| Tag | C-His |
| Bio-activity | Not validated for activity |
Properties
| Purity | > 95 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
Background
Ly6/PLAUR domain containing3 (LYPD-3) is a GPI-linked protein. The structure of LYPD-3 is similar to the urokinasetype plasminogen activator receptor (uPAR). LYPD-3 is a 6 -100 kDa molecule with variable cell type-specific N-O-linked glycosylation; mature human LYPD-3 contains two uPAR/Ly6 domains and a Ser/Thr/Pro-rich (STP) region includes a protease sensitive site . The interaction of LYPD-3 with Laminin 1 and 5 on neighboring cells promotes the adhesion; spreading; and migration of tumor cells. LYPD-3 additionally interacts with Galectin-3 and the anterior gradient proteins AG-2 and AG-3. LYPD-3 overexpression in non-small cell lung cancer is predictive of increased mortality.